

April 13, 2021

SPECIAL BULLETIN

Special Bulletin

Division of Public Health (DPH) Shares Concerns Regarding Johnson & Johnson COVID-19 Vaccine

Statement from DPH:

The Division of Public Health shares the FDA's and CDC's concerns regarding the six cases of blood clots nationwide, among those who received the Johnson & Johnson (J&J) vaccine. We appreciate that the FDA, CDC and the Advisory Committee on Immunization Practices (ACIP) are looking into data from the US and abroad to assess whether there may be a causal link between the J&J vaccine and blood clots.

We are unaware of any issues of blood clots in Delaware that may be related to this vaccine.

Out of an abundance of caution, we are recommending that our Delaware vaccine partners hold off on using the J&J vaccine until the situation has been further assessed. The state will not use J&J at its vaccination sites until we receive further federal guidance.

At this time per the CDC, these adverse events appear to be extremely rare. The effects that would indicate a blood clot are different than the usual and expected side effects of a vaccine. People who have received the J&J vaccine who develop severe headache, abdominal pain, leg pain, or shortness of breath within three weeks after vaccination should contact their health care provider.

For the Joint CDC and FDA Statement on Johnson & Johnson COVID 19 Vaccine, please visit <https://tinyurl.com/cdcfdajjvaccine>.

MSD Physician Relations

Lynn Robinson, Director
302-224-5198
Lynn.robinson@medsocdel.org

Kristie Stewart, Coordinator
302-224-5196
Kristie.Stewart@medsocdel.org